Inclusion Criteria [clinicaltrials_vocabulary:Inclusion-Criteria]
negative pregnancy test for women able to have children [clinicaltrials_resource:00001d8e827435c8e93afb66f500fcb8]No prior New York Heart Association class I-IV heart disease [clinicaltrials_resource:00003e83924167ab147f1d1c1b4593d2]serum creatinine ≤ 1.5×ULN or Creatinine clearance ≥ 60 mL/min [clinicaltrials_resource:0000411ab9e3c4561cb8829c6124638e]Hemoglobin < 12.0 g/dL [clinicaltrials_resource:00004f03d23b4d71b15234f2e1863411]Chemotherapy/Cell
Infusion).
18. Serum ALT less than three times the upper limit of normal. (Turnstile II -
Chemotherapy/Cell Infusion- Inclusion Criteria).
19. Serum creatinine less than or equal to 1.6 mg/dl. (Turnstile II [clinicaltrials_resource:00005bb5a8a13d989221656efc37828d]Daily GC (prednisone or deflazacort) therapy for > 12 months [clinicaltrials_resource:0000907adbe4924012b8acaf5fe7481b]Abnormal electrocardiogram with at least two components (complete RBBB or LBBB; left
anterior or posterior fascicular block; ventricular premature beat; first degree
atrioventricular [AV] block; Mobitz type I AV block; sinus bradycardia; primary ST-T
changes; abnormal Q waves; low voltage QRS; or atrial fibrillation); [clinicaltrials_resource:0000b2f11bbe7d9c32ae396cacebeee8](2)Fatty liver was diagnosed by abdominal echo by the same gastrologist, review by
another gastrologist [clinicaltrials_resource:0000bbd49a0f79c3cb6904d48e52bf86]Voluntary consent before performance of any study-related procedure [clinicaltrials_resource:0000c00b9d767b503bdcd78094f6a03f]Subunit or killed vaccines within 14 days prior to enrollment. [clinicaltrials_resource:0000c36e350001ffb49411d675a4ae2e]Weight < 120 kg [clinicaltrials_resource:0000d9d4d6233a44a99f07abd5dcd1de]Prostate cancer diagnosed with prostate biopsy [clinicaltrials_resource:0000e6247a7082215eb6297e0994519e]Women of non-child bearing potential or negative serum pregnancy test at Screening,
and agrees to acceptable contraceptive methods used consistently and correctly
Screening until 14 days after final visit. [clinicaltrials_resource:0001294c9f33d446760841cbefbd2834]INCLUSION CRITERIA FOR AUTOLOGOUS TRANSPLANT [clinicaltrials_resource:0001321991fc74649efcbda053cdf128]Pugh class B or C) [clinicaltrials_resource:000144ce7f64e212db138cd633d795c5]adults > 18 years of age [clinicaltrials_resource:0001517b46552fd77b03f5c3bbe6d1e8]Males and females >40 years old; [clinicaltrials_resource:0001a66f780bc900f5e8469be518065a]Use of Enbrel within 56 days of study medication initiation [clinicaltrials_resource:0002034dde2403bc4d55dcc844ac15f9]Patients with a history of non-breast malignancies are eligible if they have been
disease-free for 5 or more years prior to randomization and are deemed by their
physician to be at low risk for recurrence. Patients with the following cancers are
eligible if diagnosed and treated within the past 5 years: carcinoma in situ of the
cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous
cell carcinoma of the skin. [clinicaltrials_resource:00021add89f6e8762ed4da2e67319935]Measurable disease (NHL: At least 1 measurable site of disease [>1.5 centimeter [cm]
in the long axis regardless of short axis measurement or >1.0 cm in the short axis
regardless of long axis measurement, and clearly measurable in 2 perpendicular
dimensions]) [clinicaltrials_resource:00022ffba0df7eeab4995a79df0058a5]Male or female outpatients > 18 years of age with a primary psychiatric diagnosis of
generalized anxiety disorder [clinicaltrials_resource:000230be87c92f29833f17aa2a4637ad]Participants must have histologically confirmed advanced malignancy that is either
metastatic and/or unresectable and/or recurrent, with confirmed inactivating
mutations in TSC1 or TSC2, or activating mutations in MTOR, identified in any
CLIA-certified laboratory. All genetic findings must be reviewed by the study PI,
Dr. David Kwiatkowski, prior to study entry. [clinicaltrials_resource:000258034720c22a57965c32d4435387]White blood cells (WBC) >= 3000/mm^3 [clinicaltrials_resource:0002889e13f77d27bad99b6cb8bb28f6]Gross facet joint changes requiring fusion for treatment. [clinicaltrials_resource:0002974e65dabcefe23bff8c7f247f81]Marrow: WBC ≥ 3000/mm3, ANC ≥ 1500/mm3 , Hgb ≥ 8.0 g/dl, platelets ≥ 100,000/mm3 [clinicaltrials_resource:000299fa429ff8a4430ff1755aebe3fe]Parkinson's disease idiopathic evolving for more than 5 years [clinicaltrials_resource:0002b96a962b120dcbdb7187a50a705c]Ability to read at a fifth grade level, as assessed by the Rapid Estimate of
Adolescent Literacy in Medicine (REALM)-TEEN; and [clinicaltrials_resource:0002cce008778c2b4ada9ab7104be462]Healthy (healthy is defined as the absence of clinically-relevant abnormalities
identified by a detailed medical history, full physical examination, 12-lead ECG and
clinical laboratory tests). [clinicaltrials_resource:0002da0b7bf1f7ac81d93beb1654c32c]Patient must have MRI of brain obtained within two weeks of study initiation for
staging and patients must also receive first dose within two weeks of study
enrollment [clinicaltrials_resource:0002db763463224848b44289a129958e]a child of either sex, treated for VL in the past, currently with skin lesions like
PKDL, positive for rK39 test, and positive for Leishmania LD bodies by microscopy and
/ DNA by qPCR in their skin specimens [clinicaltrials_resource:0002f04f75ded4f9d535283862629f1c]Must be >/= 18 years old and able to provide consent [clinicaltrials_resource:000310608624c424591e0d17baa97775]1. Histologically confirmed adenocarcinoma of the stomach or gastro-oesophageal junction
with inoperable locally advanced or recurrent and/or metastatic disease not amenable
to curative therapy.
2. Measurable disease, according to the Response Evaluation Criteria in Solid Tumours
(RECIST), assessed using imaging techniques (CT or MRI)
3. ECOG Performance status 0, 1 or 2 (see Appendix 2)
4. Life expectancy of at least 3 months
5. Male or female age ≥ 18 years.
6. Signed informed consent.
7. Assessment of HER2 status (primary tumour or metastasis) by the central laboratory
prior to initiation of study treatment (see section 9.1)
8. Able to swallow and retain oral medication.
9. LVEF ≥ 50% assessed by multigated radionucleotide angiography (MUGA) or cardiac
ultrasound. [clinicaltrials_resource:00031491b1daafcda768b012f8dbaadc]Newly Diagnosed Subjects [clinicaltrials_resource:000316f55fd0d53b9b3448595350ae07]1. Frail older patients with type 2 diabetes without adequate glycemic control (HbA1c
>8.0%, >64 mmol/mol) while on metformin treatment. A previous diagnosis of type 2
diabetes mellitus will have met ADA criteria. Frailty will be identified by using the
easy to use Clinical Frailty Scale (see appendix) with patients being described as
point 4 (vulnerable), or point 5 (mildly frail), or point 6 (moderately frail (18).
2. Patient understands the study procedures, alternative treatments available, and risks
involved with the study, and voluntarily agrees to participate by giving written
informed consent.
3. Patient is a male or female and >70 years of age on the day of signing informed
consent. [clinicaltrials_resource:0003207216ed5f435a449b4569f2bc86]The target lumpectomy cavity must be clearly delineated. [clinicaltrials_resource:00032fb4d9206f29f80c7d710d5cda6f]Ability to speak English or Spanish. Ability to provide informed consent (or have a
representative able to do so). Age greater than or equal to 18 years. [clinicaltrials_resource:000346d4e9570a18847c66af27c66baf]Patients must have failed standard therapy or for whom no standard therapy exists. [clinicaltrials_resource:00037583b9d5f2fadbf435754dcf2efd]Histologically or cytologically confirmed solid cancer with/without evidence of
locally advanced or metastatic disease (Appendix B). [clinicaltrials_resource:00038408bd7ccb9b41b9fb9b09a9bb68]Diagnosed with diabetes mellitus. [clinicaltrials_resource:00039942cf70a625cf000b552e6e2d60]If the subject is currently on statin therapy, they need to have been on statin
therapy for at least 3 months prior to Screening 1. Subjects who have recently
discontinued statin therapy must "wash-out" for at least one month prior to Screening
1. [clinicaltrials_resource:0003b5dae505d818b8174b763409eb38]
type
Inclusion Criteria [clinicaltrials_vocabulary:Inclusion-Criteria]
Bio2RDF identifier
Inclusion-Criteria
Bio2RDF namespace
clinicaltrials_vocabulary
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_vocabulary:Inclusion-Criteria
identifier
clinicaltrials_vocabulary:Inclusion-Criteria
title
Inclusion Criteria
@en
label
Inclusion Criteria [clinicaltrials_vocabulary:Inclusion-Criteria]
@en